© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
GLP-1 Drug Prescribing Trends Mirror Rise in US Obesity Rates
June 27, 2025
Obesity treatment evolves as GLP-1 medication use surges 587%, while bariatric surgery rates decline significantly. A new analysis parses the trends.
10 Questions on Holiday Alcohol Habits in the US
June 27, 2025
July 4th invites celebration, typically with alcohol. Try our quiz based on a review of the holiday drinking patterns of US adults. Are answers to these 10 questions what you expect?
Alzheimer Screening in Primary Care Feasible but Rare: Daily Dose
June 27, 2025
Your daily dose of the clinical news you may have missed.
Roflumilast Cream 0.15% Receives Strong Recommendation for Atopic Dermatitis in AAD Guideline Update
June 26, 2025
Roflumilast 0.15% is the only 1 of 4 newly evaluated branded topical therapies to receive the Academy's strong recommendation for AD management in adults.
Only Half of Patients Adherent to Antidementia Medication Regimens at 1 Year: New Meta-Analysis Results
June 26, 2025
Suboptimal adherence with antidementia drugs is associated with poorer clinical outcomes including accelerated disease progression and symptomatology.
Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial
June 26, 2025
ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.
Viking Advances GLP-1/GIP Agonist VK2735 into Late Stage Clinical Program for Obesity
June 26, 2025
Viking Therapeutics initiates phase 3 trials for VK2735, a promising dual incretin agonist targeting obesity and other metabolic disorders, based on strong phase 2 findings.
ctDNA Blood Test Detected 79% of Colorectal Cancers in Screening Study: Daily Dose
June 26, 2025
Your daily dose of the clinical news you may have missed.
Why Is Early Treatment of Atopic Dermatitis So Important? Mona Shahriari, MD, Says It Could Change a Life
June 26, 2025
Atopic dermatitis is not just "another rash on the schedule. It could be the reason that patient doesn't leave the house," Shahriari says.
Investigational Rezpegaldesleukin Drives Early EASI Improvement and Symptom Relief in Adults with Moderate-to-Severe Atopic Dermatitis
June 25, 2025
In the phase 2b trial, the IL-2 pathway agonist and Treg proliferator demonstrated a strong dose-dependent biological response across 3 treatment arms vs placebo.